Collegium Pharmaceutical (COLL) vs. Its Competitors Financial Analysis

Collegium Pharmaceutical (NASDAQ:COLL) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Collegium Pharmaceutical to related businesses based on the strength of its valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and earnings.

Earnings & Valuation

This table compares Collegium Pharmaceutical and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57 million	$62.87 million	19.14
Collegium Pharmaceutical Competitors	$3.55 billion	$3.17 billion	547.98

Collegium Pharmaceutical’s competitors have higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Collegium Pharmaceutical and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
Collegium Pharmaceutical Competitors	-2,372.59%	-220.83%	-15.99%

Analyst Ratings

This is a summary of current ratings for Collegium Pharmaceutical and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	1	1	6	1	2.78
Collegium Pharmaceutical Competitors	7769	13855	25724	1032	2.41

Collegium Pharmaceutical currently has a consensus target price of $48.71, indicating a potential upside of 105.29%. As a group, “Pharmaceuticals” companies have a potential upside of 25.36%. Given Collegium Pharmaceutical’s stronger consensus rating and higher possible upside, equities analysts plainly believe Collegium Pharmaceutical is more favorable than its competitors.

Institutional & Insider Ownership

32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Collegium Pharmaceutical has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical’s competitors have a beta of -3.79, suggesting that their average share price is 479% less volatile than the S&P 500.

Summary

Collegium Pharmaceutical beats its competitors on 8 of the 13 factors compared.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.